Phase 2
Completed N=23
Beta Glucosylceramide for Treatment of NASH
Compliance Behavior
Source: ClinicalTrials.gov NCT02126306 ↗
Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcomePrimary: Number of Participants With a Decrease of 2 Points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) Analysis is Per Protocol — 10; 13 participants
Summary
Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With a Decrease of 2 Points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) Analysis is Per Protocol |
10; 13 | — |
Eligibility Criteria
Inclusion Criteria
- Biopsy proven NASH
Exclusion Criteria
- Other therapies
Data sourced from ClinicalTrials.gov (NCT02126306). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.